Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Obagi - C
Overview
What is Obagi - C?
Hydroquinone is 1,4 - bensenediol. Hydroquinone occurs as fine, white needles. The drug is freely
soluble in water and in alcohol. Chemically, hydroquinone is designated as p - dihydroxybenzene;
the empirical formula is C6H6O2; molecular weight is 110.11 g / moL.
What does Obagi - C look like?

What are the available doses of Obagi - C?
Sorry No records found.
What should I talk to my health care provider before I take Obagi - C?
Sorry No records found
How should I use Obagi - C?
The gradual bleaching of hyperpigmented skin conditions such as chloasma, melasma, freckles,
senile lentigines, and other unwanted areas of melanin hyperpigmentation.
A thin application should be applied once or twice daily or as directed by a physician. no
improvement is seen after three (3) months of treatment, use of this product should be
discontinued. Sun exposure may be limited by using a sunscreen agent, a sunblocking agent,
or protective clothing to cover bleached skin when using and after using this product in order to
prevent darkening from reoccuring.
What interacts with Obagi - C?
Sorry No Records found
What are the warnings of Obagi - C?
Sorry No Records found
What are the precautions of Obagi - C?
Sorry No Records found
What are the side effects of Obagi - C?
Sorry No records found
What should I look out for while using Obagi - C?
People with prior history of sensitivity or allergic reaction to this product or any of its
ingredients should not use it. The safety of topical hydroquinone use during pregnancy
or in children (12 years and under) has not been established.
Hydroquinoone is a skin - bleaching agent, which may produce unwanted cosmetic effects if not
used as directed. The physician should be familiar with the contents of this insert before prescribing
or dispensing this product.
Test for skin sensitivity before using by applying a small amount to an unbroken patch of skin
and check within 24 hours. Minor redness is not a contraindication, but where there is itching
or vesicle formation or excessive inflammatory response, product should be discontinued and
physician consulted. Close patient supervision is recommended.
Avoid contact with eyes, nose, mouth, and lips. In case of accidental contact, patient should
rinse thoroughly with water and contact a physician.
Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight
exposure sustains melanocytic activity.
The Obagi - C Rx Therapy Night Cream contains sodium metabisulfite, a sulfite that
may cause allergic - type reactions including anaphylactic symptoms and life - threatening or
less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite
sensitivity in the general populationis unknown and probably low. Sulfite sensitivity is seen
more frequently in asthmatic than in nonasthmatic people.
What might happen if I take too much Obagi - C?
Sorry No Records found
How should I store and handle Obagi - C?
Sorry No Records found
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Topical application of hydroquinone produces a reversible depigmentation of the skin by
inhibition of the enzymatic oxidation of 3, 4 - dihydroxyphenylalanine (DOPA) and
suppression of other melanocyte metabolic processes. Exposure to sunlight or ultraviolet light
will cause repigmentation of the bleached areas, which may be prevented by the use of
sunblocking agents or sunscreen agents contained in the Obagi - C Rx System sun Shield Matte
Broad Spectrum SPF 50.
Non-Clinical Toxicology
People with prior history of sensitivity or allergic reaction to this product or any of itsingredients should not use it. The safety of topical hydroquinone use during pregnancy
or in children (12 years and under) has not been established.
Hydroquinoone is a skin - bleaching agent, which may produce unwanted cosmetic effects if not
used as directed. The physician should be familiar with the contents of this insert before prescribing
or dispensing this product.
Test for skin sensitivity before using by applying a small amount to an unbroken patch of skin
and check within 24 hours. Minor redness is not a contraindication, but where there is itching
or vesicle formation or excessive inflammatory response, product should be discontinued and
physician consulted. Close patient supervision is recommended.
Avoid contact with eyes, nose, mouth, and lips. In case of accidental contact, patient should
rinse thoroughly with water and contact a physician.
Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight
exposure sustains melanocytic activity.
The Obagi - C Rx Therapy Night Cream contains sodium metabisulfite, a sulfite that
may cause allergic - type reactions including anaphylactic symptoms and life - threatening or
less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite
sensitivity in the general populationis unknown and probably low. Sulfite sensitivity is seen
more frequently in asthmatic than in nonasthmatic people.
(also see WARNINGS)
Treatment should be limited to relatively small areas of the body at one time since some
patients experience a transient skin reddening and a mild burning sensation, which does not
preclude treatment.
Pregnancy Category C
Animal reproduction studies have not been conducted with topical hydroquinone. It is also
not known whether hydroquinone can case fetal harm when used topically on a pregnant woman
or affect reproductive capacity. It is not known to what degree, if any, topical hydroquinone is
absorbed systemically. Topical hydroquinone should be used on pregnant women only when
clearly indicated.
Nursing Mothers
It is not known whether topical hydroquinone is absorbed or excreted in human milk. Caution is
advised when topical hydroquinone is used by a nursing mother.
Pediatric Usage
Safety and effectiveness in children below the age of 12 years have not been established.
No systemic adverse reactions have been reported. Occasional hypersensitivity (localized
contact dermatitis) may occur, in which case the product should be discontinued and physician
notified immediately.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).